Metastatik Meme Kanseri: Sistemik Tedavi, Lokal Tedaviler ve Palyatif Bakım

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May;74(3):229–63.

Bochenek-Cibor J, Górecka M, Storman D, Bała MM. Support for Metastatic Breast Cancer Patients—a Systematic Review. Vol. 35, Journal of Cancer Education. Springer; 2020. p. 1061–7.

T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. Türkiye Kanser İstatistikleri Raporu. Ankara; 2020.

Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;(321(3):288-300).

Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Annals of Oncology. 2021 Dec 1;32(12):1475–95.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 4.2024. Available from: https://www.nccn.org

Huppert LA, Gumusay O, Idossa D, Rugo HS. Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer. CA Cancer J Clin. 2023 Sep;73(5):480–515.

Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022;(40(28):3246-3256.

Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;(375(20):1925–1936.

Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;(375(18):1738–1748.

Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib as Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;(35(32):3638–3646.

Juric D, Rodon J, Tabernero J, et al. Phosphatidylinositol 3‐kinase α‐selective inhibition with alpelisib (BYL719) in PIK3CA‐altered solid tumors: results from the first‐in‐human study. J Clin Oncol. 2018;36(13):1291‐129.

Jones RH, Casbard A, Carucci M, et al. Fulvestrant plus cap- ivasertib versus placebo after relapse or progression on an aro- matase inhibitor in metastatic, oestrogen receptor‐positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2020;21(3):345‐357).

Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone‐receptor‐positive, human epidermal growth factor receptor‐2‐negative advanced breast cancer: overall survival results from BOLERO‐2. Ann Oncol. 2014;5(12): 2357‐2362.

Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023;388(22):2058-2070.

Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2‐negative metastatic breast cancer. Ann Oncol. 2019;30(4): 558‐566.

Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2008;379(8):753‐763.

Khongorzul P, Ling CJ, Khan FU, et al. Antibody‐drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18(1): 3‐19.

Rugo HS, Bardia A, Marmé F, et al. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol. 2022;40(29):3365-3376.

O’Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first‐line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440‐449.

Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open‐label randomised study. Lancet. 2011;377(9769):914‐923.

Dempsey N, Sandoval A, Mahtani R. Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy? Vol. 24, Current Treatment Options in Oncology. 2023;24:1120–37.

Avelino ARM, Pulipati S, Jamouss K, Bhardwaj P V. Updates in Treatment of HER2-positive Metastatic Breast Cancer. Vol. 25, Current Treatment Options in Oncology. 2024;25:1471–81.

Cortés J, Kim SB, Chung WP, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022;386:1143–54.

Powell CA, Modi S, Iwata H, Takahashi S, Smit EF, Siena S, et al. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 2022;7(4):100554.

Curigliano G, Mueller V, Borges V, et al. Tucatinib versus placebo added to trastuzumab and capecit- abine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol . 2022;33:321–9.

Murthy RK, Loi S, Okines A, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020;382(7):597-609.

Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387(3):217-226.

Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523-533.

Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021;384(16):1529-1541.

Pauls M, Chia S, Levasseur N. Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer. Vol. 29, Current Oncology. 2022;29:4748–67.

Khan SA, Zhao F, Solin LJ, et al. A Randomized Phase III Trial of Systemic Therapy Plus Early Local Therapy Versus Systemic Therapy Alone in Women With De Novo Stage IV Breast Cancer: A Trial of the ECOG-ACRIN Research Group (E2108). J Clin Oncol. 2022;40(9):978-987.

Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16(13):1380-1388.

Budach W, Bölke E, Matuschek C. Radiotherapy of metastatic breast cancer. Breast Care (Basel). 2013;8(4):257-63.

Lutz S, Balboni T, Jones J, et al. Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017;7(1):4-12.

Possanzini M, Greco C. Stereotactic radiotherapy in metastatic breast cancer. Vol. 41, Breast. Churchill Livingstone; 2018;41:57–66.

Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009;115(3):601-8.

Richman CM, Denardo SJ. Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies. Crit Rev Oncol Hematol. 2001;38(1):25-35.

Ahmad A. Breast Cancer Metastasis and Drug Resistance [Internet]. Cham: Springer International Publishing; 2019. (Advances in Experimental Medicine and Biology; vol. 1152). Available from: http://link.springer.com/10.1007/978-3-030-20301-6

Shao H, Varamini P. Breast Cancer Bone Metastasis: A Narrative Review of Emerging Targeted Drug Delivery Systems. Cells. 2022;11(3):388.

Coleman R HPBJ et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(12):1650-1663.

Wang Y, Ye F, Liang Y, Yang Q. Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies. Br J Cancer. 2021;125:1056–67.

Lin NU, Amiri-Kordestani L, Palmieri D, et al. Breast cancer brain metastases: New directions in systemic therapy. Ecancermedicalscience . 2013;7:307.

Raghavendra AS, Ibrahim NK. Breast Cancer Brain Metastasis: A Comprehensive Review. JCO Oncol Pract. 2024;20(10):1348–59.

Jin L, Han B, Siegel E, Cui Y, Giuliano A, Cui X. Breast cancer lung metastasis: Molecular biology and therapeutic implications. Cancer Biology and Therapy. Cancer Biol Ther. 2018;19(10):858–68.

Zuo Q, Park NH, Lee JK, Erdogan ZM. Liver Metastatic Breast Cancer: Epidemiology, Dietary Interventions, and Related Metabolism. Nutrients. 2022;14(20):4416.

Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11-48.

Cleary J, Ddungu H, Distelhorst SR, Ripamonti C, Rodin GM, Bushnaq MA, et al. Supportive and palliative care for metastatic breast cancer: Resource allocations in low- and middle-income countries: A breast health global initiative 2013 consensus statement. Breast. 2013;22:616–27.

Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-42.

Cherny NI, Paluch-Shimon S, Berner-Wygoda Y. Palliative care: Needs of advanced breast cancer patients. Breast Cancer: Targets and Therapy (Dove Medical Press). 2018;10:231–43.

Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv166-iv191.

Ferrell BR, Temel JS, Temin S, et al. Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35(1):96-112.